Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Biotechnology Cancer Cures -- Ignore unavailable to you. Want to Upgrade?

To: Pseudo Biologist who wrote (117)	10/11/1999 5:10:00 PM
From: tnsaf	Respond to of 226

Abstract of article in Nature Medicine October 1999 Volume 5 Number 10 pp 1171 - 1177 Complete molecular remissions induced by patient-specific vaccination plus granulocyte?monocyte colony-stimulating factor against lymphoma Maurizio Bendandi1, Christopher D. Gocke4, Carol B. Kobrin5, Floyd A. Benko4, Lars A. Sternas1, Robin Pennington5, Thelma M. Watson1, Craig W. Reynolds2, Barry L. Gause1, Patricia L. Duffey6, Elaine S. Jaffe3, Stephen P. Creekmore2, Dan L. Longo6 & Larry W. Kwak1 Lymphomas express a tumor-specific antigen which can be targeted by cancer vaccination. We evaluated the ability of a new idiotype protein vaccine formulation to eradicate residual t(14;18)+ lymphoma cells in 20 patients in a homogeneous, chemotherapy-induced first clinical complete remission. All 11 patients with detectable translocations in their primary tumors had cells from the malignant clone detectable in their blood by PCR both at diagnosis and after chemotherapy, despite being in complete remission. However, 8 of 11 patients converted to lacking cells in their blood from the malignant clone detectable by PCR after vaccination and sustained their molecular remissions. Tumor-specific cytotoxic CD8+ and CD4+ T cells were uniformly found (19 of 20 patients), whereas antibodies were detected, but apparently were not required for molecular remission. Vaccination was thus associated with clearance of residual tumor cells from blood and long-term disease-free survival. The demonstration of molecular remissions, analysis of cytotoxic T lymphocytes against autologous tumor targets, and addition of granulocyte?monocyte colony-stimulating factor to the vaccine formulation provide principles relevant to the design of future clinical trials of other cancer vaccines administered in a minimal residual disease setting.

To: Pseudo Biologist who wrote (117)	10/13/1999 2:39:00 PM
From: Mike McFarland	Read Replies (2) \| Respond to of 226

Thanks PB...I see the thread is still going, a trickle of posts-- but nice to see folks still have it bookmarked. The only thing I'm looking at lately in this area is CTIC--suggested it for the dead cat bounce on the TraderJ thread--no feedback whatsoever...and the stock is flatlined at 1 3/4. Worth a look, I'm obviously too shellshocked to pull biotech trades for awhile, but this one is close to book value. This one is local for me...that could help as far as going to meetings and such. Nice website cticseattle.com and here is their pipline page cticseattle.com I've probably mentioned PG-TXL before here, have to do the search and see... Happy hunting.